Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UBX 303061

Next Previous
X
Search
Drug Profile

UBX 303061

Alternative Names: UBX-303061

Latest Information Update: 19 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ubix Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase degraders; Proteolysis
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B-cell lymphoma

Most Recent Events

  • 06 Dec 2024 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in USA (PO) (NCT06590961)
  • 19 Sep 2024 Preclinical trials in B-cell lymphoma in South Korea (PO), prior to September 2024
  • 19 Sep 2024 Ubix Therapeutics plans a phase I trial for B-cell lymphoma (Second-line therapy or greater) (PO), in November 2024 (NCT06590961)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top